July 16, 2020
SanBio President Keita Mori SanBio aims to maximize the value of its lead cell therapy candidate SB623 by concentrating its resources on its development for traumatic brain injury (TBI) and chronic ischemic stroke, while seeking licensing partners for other indications,...read more